Search

Your search keyword '"Chopra, Nitin"' showing total 441 results
Start Over Author "Chopra, Nitin"
441 results on '"Chopra, Nitin"'

1. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina

Author

de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppälä, Niko, Kopeček, Miloslav, Švancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., González-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Hélène, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F.J., Ertuğrul, Aygün, Anıl Yağcıoğlu, A. Elif, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, López-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Rădulescu, Flavian Ştefan, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry Kit Wa, Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Cubała, Wiesław Jerzy, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagrán-Moreno, José María, Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria Rosel, Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gründer, Gerhard, Sagud, Marina, Celofiga, Andreja, Ignjatovic Ristic, Dragana, Ortiz, Bruno Bertolucci, Elkis, Helio, Pacheco Palha, António José, Llerena, Adrián, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Mohd Saffian, Shamin, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., and Müller, Daniel J.

Published
2023
Full Text
View/download PDF

5. Factors to guide the use of extended-release buprenorphine formulations for specific patient populations.

Author

Cuperfain, Ari B., Katznelson, Gali, Costa, Tianna, Wong, Patrick, Beyraghi, Narges, George, Tony P., Lofwall, Michelle R., and Chopra, Nitin

Subjects
SUBSTANCE abuse, MEDICAL information storage & retrieval systems, CONTROLLED release preparations, IMPRISONMENT, PSYCHIATRIC treatment, AT-risk people, DESCRIPTIVE statistics, SYSTEMATIC reviews, MEDLINE, PATIENT-centered care, HOMELESSNESS, CRIMINAL justice system, BUPRENORPHINE, PSYCHOLOGY information storage & retrieval systems, COMORBIDITY, PATIENTS' attitudes
Abstract

Opioid agonist therapy is first line in the management of opioid use disorder (OUD). Many guidelines support buprenorphine as the optimal treatment due to its preferred safety profile. Extended-release buprenorphine (BUP-XR) is a weekly or monthly subcutaneously administered formulation of buprenorphine. Emerging research has explored the use of BUP-XR in a variety of patient populations to guide clinicians in determining which patients may or may not benefit from BUP-XR. We conducted a literature review in Medline, PsycInfo and Embase to capture the literature to date on BUP-XR. Abstracts were reviewed, and papers which guided selection of individuals who would or would not benefit from BUP-XR were included. Our search returned 359 articles, and 31 met inclusion criteria. Special populations who may benefit from BUP-XR include individuals experiencing homelessness, incarceration, and medical or psychiatric comorbidity, while caution should be used around pregnancy. Patient preference and patient-centered outcomes were recurring considerations to guide the selection of BUP-XR. Extended-release buprenorphine formulations represent a relatively new tool for managing OUD and may specifically benefit patients undergoing transitions in care. Further research on the comparative effectiveness of extended-release versus daily-dosing formulations and in other populations of interest is needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure

Author

Yamada, Takayuki, Ueyama, Hiroki, Chopra, Nitin, Yamaji, Takahiro, Azushima, Kengo, Kobayashi, Ryu, Kinguchi, Sho, Urate, Shingo, Suzuki, Toru, Abe, Eriko, Saigusa, Yusuke, Wakui, Hiromichi, Partridge, Paulina, Burger, Alfred, Bravo, Claudio A., Rodriguez, Maria A., Ivey-Miranda, Juan, Tamura, Kouichi, Testani, Jeffery, and Coca, Steven

Published
2020
Full Text
View/download PDF

10. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis

Author

Yamada, Takayuki, Wakabayashi, Mako, Bhalla, Abhinav, Chopra, Nitin, Miyashita, Hirotaka, Mikami, Takahisa, Ueyama, Hiroki, Fujisaki, Tomohiro, Saigusa, Yusuke, Yamaji, Takahiro, Azushima, Kengo, Urate, Shingo, Suzuki, Toru, Abe, Eriko, Wakui, Hiromichi, and Tamura, Kouichi

Published
2021
Full Text
View/download PDF

12. Harnessing Harm-Reduction Methods to Combat the Opioid Crisis

Author

Izadi, Nazanin, Bahji, Anees, Chopra, Nitin, Ling, Sara, Hansen, Helena B., and George, Tony P.

Subjects
Drugs -- Overdose, Opioids -- Analysis -- Methods, Evidence-based medicine -- Analysis -- Methods, Health, Psychology and mental health
Abstract

Fentanyl and fentanyl analogues, such as carfentanil, are driving an opioid overdose crisis in North America. (1) In 2019 alone, there were 3831 opioid-related deaths in Canada (2) and 47,600 [...]

Published
2021

18. Hybrid 2D nanostructures for mechanical reinforcement and thermal conductivity enhancement in polymer composites

Author

Ribeiro, Hélio, Trigueiro, João P.C., Owuor, Peter S., Machado, Leonardo D., Woellner, Cristiano F., Pedrotti, Jairo J., Jaques, Ygor M., Kosolwattana, Suppanat, Chipara, Alin, Silva, Wellington M., Silva, Carlos J.R., Galvão, Douglas S., Chopra, Nitin, Odeh, Ihab N., Tiwary, Chandra S., Silva, Glaura G., and Ajayan, Pulickel M.

Published
2018
Full Text
View/download PDF

19. Injection mensuelle de buprenorphine a liberation prolongee

Author

Cuperfain, Ari B., Costa, Tianna, and Chopra, Nitin

Subjects
Buprenorphine -- Health aspects -- Cases, Company legal issue, Health
Abstract

1 La buprenorphine a liberation prolongee (BUP-LP) s'administre par injection souscutanee, 1 fois par mois, sous forme de << depot >>, dans le traitement de la dependance aux opioides En [...]

Published
2023
Full Text
View/download PDF

42. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

Author

de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppala, Niko, Kopecek, Miloslav, Svancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., Gonzalez-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Helene, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F. J., Ertugrul, Aygun, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, Lopez-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry K. W., Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagran-Moreno, Jose M., Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria R., Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gruender, Gerhard, Sagud, Marina, Celofiga, Andreja, Ristic, Dragana Ignjatovic, Ortiz, Bruno B., Elkis, Helio, Palha, Antonio J. Pacheco, LLerena, Adrian, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Saffian, Shamin Mohd, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., Muller, Daniel J., Anil Yagcioglu, A. Elif, Radulescu, Flavian S., Cubala, Wieslaw J., de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppala, Niko, Kopecek, Miloslav, Svancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., Gonzalez-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Helene, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F. J., Ertugrul, Aygun, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, Lopez-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry K. W., Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagran-Moreno, Jose M., Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria R., Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gruender, Gerhard, Sagud, Marina, Celofiga, Andreja, Ristic, Dragana Ignjatovic, Ortiz, Bruno B., Elkis, Helio, Palha, Antonio J. Pacheco, LLerena, Adrian, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Saffian, Shamin Mohd, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., Muller, Daniel J., Anil Yagcioglu, A. Elif, Radulescu, Flavian S., and Cubala, Wieslaw J.

Abstract

This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas' original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300-600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150-300 mg/day, and 6) in the US with ancestries other than from Asia or the original people fr

Published
2022

43. Gold nanoparticle integrated with nanostructured carbon and quantum dots: synthesis and optical properties

Author

Li, Yuan and Chopra, Nitin

Subjects
Chemical vapor deposition -- Optical properties -- Analysis, Crystals -- Structure, Nanoparticles, Fluorescence -- Optical properties -- Analysis, Gold -- Properties, Metals, metalworking and machinery industries
Abstract

Multilayer graphene shell encapsulated gold nanoparticle--quantum dot hybrids were derived by combining wetchemical, thermal, and covalent chemistry approaches. Uniformly patterned gold nanoparticles on a silicon substrate were obtained via gold film deposition in an electroless method followed by a thermal dewetting process. The resulting gold nanoparticles were further surface oxidized and utilized as catalysts for the chemical vapor deposition growth of multilayer graphene shell encapsulated on the gold nanoparticles (referred as 'multilayer graphene shell encapsulated Au nanoparticle' or graphene nanoparticles (GNPs)). As a next step, the surface of GNPs was modified to result in carboxylic (-COOH) functionalities, which enabled carbodiimide-based covalent linking of amine-terminated Cd[S.sub.x][Se.sub.1-x]@ZnS quantum dots (QDs) on the GNP surface. The GNPs and GNP-QD heterostructures were characterized using scanning and transmission electron microscopy for size, morphology, spatial distribution, and crystal structure evaluation. In addition, UV-vis, fluorescence spectroscopy, and discrete dipole approximation (DDA) modeling were utilized for understanding the band gap energies, fluorescence quenching, and light-matter interactions of the derived hybrids/heterostructures. Keywords Graphene * Gold nanoparticles * Quantum dots * Optical properties, discrete dipole approximation, Introduction The surface modification of photonic nanostructures such as gold (Au) nanoparticles can lead to novel physical phenomena including selective light-matter interactions and rapid energy transfer processes [1-3]. The surface [...]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results